The "Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market" report has been added to Research and Markets' offering. This analysis includes a discussion of products, competitors, ...

Modern medical research shows that drug and surgical treatments for benign prostatic hyperplasia and chronic prostatitis carry high risks, while Dr Allen's Device, developed by Fine Treatment, an ...

The MarketWatch News Department was not involved in the creation of this content. Oxford, UK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Topical summits in Dubai, Berlin, Nanjing, Basel, Lisbon, London and ...

Clinical studies of Dr Allen’s US Patented Thermobalancing Therapy in men with benign prostatic hyperplasia or benign prostatic enlargement (BPE or BPH) have demonstrated the efficacy and safety of ...

ProUroCare Medical, Inc., of Minneapolis, Minn., has filed a de novo application with the FDA seeking marketing clearance for its prostate mechanical imaging (PMI) device (ProUroScan). This will allow ...

Less than a week after making a regulatory submission for a $1 million capital raise, prostate health company ProUroCare Medical, based in Eden Prairie, Minnesota, announced that it has secured market ...

Transrectal ultrasound guided (TRUS) biopsy has been the gold standard for prostate cancer diagnosis, but carries a significant risk of urinary tract infection, sometimes requiring hospital admission ...

WEST LAFAYETTE, Ind. - A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease. A team of Purdue University researchers has synthesized ...

The distinctiveness of Dr Allen Device lies in its approach to treating the core of chronic pain and other chronic conditions. Dr Allen Device vs painkillers, which change the way the brain and ...

The distinctiveness of Dr Allen Device lies in its approach to treating the core of chronic pain and other chronic conditions. Dr Allen Device vs painkillers, which change the way the brain and ...